(Press-News.org) SAN ANTONIO (May 29, 2024) – SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions. A consortium of scientists at Texas Biomedical Research Institute (Texas Biomed), the University of Alabama at Birmingham (UAB) and Columbia University have developed a promising new human monoclonal antibody that appears a step closer to a universal antibody cocktail that works against all strains of SARS-CoV-2.
“This antibody worked against the original SARS-CoV-2 strain, Omicron and SARS-CoV, providing strong evidence that this antibody will continue to work against future strains, especially if paired with other antibodies,” says Luis Martinez-Sobrido, Ph.D., a Professor at Texas Biomed and co-lead author of the research, which is published as a preprint on BioRXiv.
Antibodies are part of the human immune system that track, bind to and destroy extraneous material like viruses and bad bacteria. Human monoclonal antibodies are lab-made proteins that mimic the human process and stimulate the body to produce its own antibodies, enhancing the ability to fight back against illnesses.
While existing antibody treatments have helped many patients with COVID-19, some treatments have been rendered infective because the virus evolved and the antibodies could no longer physically bind to the targeted region – in other words, the key no longer fit the lock.
The newly designed antibody, called 1301B7, is a receptor binding domain antibody, meaning it targets a region of the spike protein responsible for enabling the virus to bind and enter a cell. By targeting this region, these antibodies are essentially stopping the virus before they can infect a cell.
“The antibody binds to multiple positions within the receptor binding domain, which is thought to enable it to tolerate variations that occur in this domain as the virus continues to evolve,” says James Kobie, Ph.D., an Associate Professor at UAB and co-lead author of the paper. The precise nature of how the antibody binds to the receptor binding domain was solved by Mark Walter, Ph.D., a Professor at UAB and co-lead paper author.
The monoclonal antibody is designed based on antibodies the UAB team isolated from patients infected with the Omicron variant of SARS-CoV-2. The teams at Texas Biomed and Columbia University tested the antibody against several variants including the original SARS-CoV-2 isolated in China, Omicron JN.1 and SARS-CoV.
In 2022, the researchers described a monoclonal antibody targeting a different part of the spike called the stalk. The researchers plan to next study what happens when they combine the two antibodies together, attacking the virus from different angles and hopefully preventing it from escaping neutralization.
“A single antibody therapy is not going to work, so we may have to try something similar to therapies being developed for other diseases like Ebola and HIV whereby two or three antibodies are combined to target different regions of the virus,” explains Dr. Martinez-Sobrido.
They are also interested in adapting the antibodies into a preventative vaccine.
“We are also trying to design vaccines that would be able to induce these types of antibodies so we don’t have to update vaccines regularly,” says Dr. Martinez-Sobrido.
The consortium of scientists has filed a provisional invention patent for 1301B7 and is in the process of licensing it for commercialization.
—
Scientists from Dr. Martinez-Sobrido’s lab at Texas Biomed involved in this study include Ahmed Magdy Khalil, Ph.D., Ahmed Mostafa, Ph.D., Yao Ma, Ph.D. and Chengjin Ye, Ph.D.
Funding for this work was largely provided by the National Institutes of Health 1R01AI161175.
About Texas Biomed
Texas Biomed is a nonprofit research institute dedicated to protecting the global community from infectious diseases. Through basic research, preclinical testing and applied innovation, we accelerate diagnostics, therapies and vaccines for the world’s deadliest pathogens. Our San Antonio campus hosts high containment laboratories and the Southwest National Primate Research Center. Our scientists collaborate with industry and researchers globally, and have helped deliver the first COVID-19 vaccine, the first Ebola treatment and first Hepatitis C therapy. For more information, visit txbiomed.org.
END
Researchers take step toward development of universal COVID-19 antibodies
Texas Biomed and partners licensing new SARS-CoV-2 antibody targeting newest strains of COVID-19
2024-05-29
ELSE PRESS RELEASES FROM THIS DATE:
Do epilepsy medications taken during pregnancy affect a child’s creativity?
2024-05-29
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, MAY 29, 2024
MINNEAPOLIS – While older drugs for epilepsy, taken while pregnant, have been shown in previous research to affect the creative thinking of children, a new study finds no effects on creativity for children born to those taking newer epilepsy drugs. This study is published in the May 29, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Overall, the study found no effects on the children’s creative abilities or their executive function, which is a person’s ability to plan, focus, and manage multiple tasks. However, when ...
First hints of memory problems associated with changes in the brain
2024-05-29
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, MAY 29, 2024
MINNEAPOLIS – People who report early memory problems and whose partners also suspect they have memory problems have higher levels of tau tangles in the brain, a biomarker associated with Alzheimer’s disease, according to a study published in the May 29, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Subjective cognitive decline is when a person reports memory and thinking problems before any decline is large enough to show up on standard tests.
“Understanding the earliest signs of Alzheimer’s disease is even more important ...
Mass General Brigham study finds that memory complaints can predict biological changes in the brain
2024-05-29
Researchers found that reports from patients and their partners about cognitive decline were associated with the accumulation of tau, a hallmark of Alzheimer’s disease
A new study adds further evidence that when a patient or family member notices signs of persistent memory loss, it’s important to speak with a doctor. While there are many reasons why someone’s memory may change, researchers from Mass General Brigham who are studying patients prior to diagnosis with Alzheimer’s disease found changes in the brain when patients and their study partners—those who could answer questions about their ...
JPMorgan Chase, Argonne and Quantinuum show theoretical quantum speedup with the quantum approximate optimization algorithm
2024-05-29
In a new paper in Science Advances on May 29, researchers at JPMorgan Chase, the U.S. Department of Energy’s (DOE) Argonne National Laboratory and Quantinuum have demonstrated clear evidence of a quantum algorithmic speedup for the quantum approximate optimization algorithm (QAOA).
This algorithm has been studied extensively and has been implemented on many quantum computers. It has potential application in fields such as logistics, telecommunications, financial modeling and materials science.
“This work is a significant step towards reaching quantum advantage, ...
AI browser plug-ins to help consumers improve digital privacy literacy, combat manipulative design
2024-05-29
Researchers at the University of Notre Dame are developing artificial intelligence tools that help consumers understand how they are being exploited as they navigate online platforms. The goal is to boost the digital literacy of end users so they can better control how they interact with these websites.
In a recent study, participants were invited to experiment with online privacy settings without consequence. To test how different data privacy settings work, the researchers created a Chrome browser plug-in called Privacy Sandbox that replaced participant data with personas generated by GPT-4, a large language model from OpenAI.
With Privacy Sandbox, participants could ...
Grant funds CU project to develop novel mechanism to expand NF1 treatments
2024-05-29
The Gilbert Family Foundation has awarded data scientists in the Department of Biomedical Informatics (DBMI) at the University of Colorado School of Medicine $1.2 million to develop a microscopy assay and analysis pipeline for organoids derived from patients with Neurofibromatosis 1 (NF1), a complex rare disease that causes tumors to grow along nerves and produces a range of symptoms.
The project will help researchers develop more treatments for the disease, says DBMI assistant professor Gregory ...
A drying Salton Sea pollutes neighboring communities
2024-05-29
When desert winds stir up dust from the Salton Sea’s exposed lakebed, nearby communities suffer from increased air pollution. The deterioration coincides with reduced flows into California’s largest lake, a new research paper in the American Journal of Agricultural Economics finds.
Disadvantaged communities have been affected more than others in the areas near the Salton Sea, which has been shrinking for years, said the paper’s co-leading author Eric Edwards. He is an assistant professor of agricultural economics at University of California, Davis, who did the research while at North Carolina State University.
“We ...
Wild megalopolis: Study shows unexpected pockets of biodiversity pepper Los Angeles
2024-05-29
UCLA biologists have some good news and some bad news for lovers of urban wildlife in Los Angeles. The good news? Unexpected pockets of biodiversity pepper the city. The bad news? It will be a challenge to elevate the level of overall biodiversity of the city. Of all the major taxonomic groups studied, only snails and slugs are ‘easy’ to find in Los Angeles, probably because of the abundance of landscaping, gardens and irrigation.
The research points toward ways Angelenos — and people elsewhere — can make their city more hospitable not only to urban-tolerant species such as coyotes, but also to species that usually ...
Slugs and snails love the city, unlike other animals
2024-05-29
Most native species avoid more urbanized areas of Los Angeles, but slugs and snails may actually prefer these environments, according to a study publishing May 29 in the open-access journal PLOS ONE by Joseph Curti from the University of California, Los Angeles, and colleagues.
Urban areas continue to grow around the world, putting pressure on native species that find it difficult to tolerate the habitat changes and pollution it brings. To conserve and even increase biodiversity in cities, scientists and city planners need large-scale data on the ecological communities present, but this is time consuming and difficult to collect. Researchers used data from iNaturalist, a large ...
Ideas that cross international borders may have powerful impact on elections
2024-05-29
New simulations provide mathematical support for the theory that the spread of political ideas across international borders may have a big impact on election outcomes, and that small actions boosting a minority idea can gradually lead to global-scale political change. Jose Segovia-Martin and Óscar Rivero present these findings in the open-access journal PLOS ONE on May 29.
People in many regions around the world are increasingly exposed to international information—such as news and opinions shared via social media—allowing for the possibility of ...
LAST 30 PRESS RELEASES:
Insulin resistance is linked to over 30 diseases – and to early death in women, study of people in the UK finds
Innovative semaglutide hydrogel could reduce diabetes shots to once a month
Weight loss could reduce the risk of severe infections in people with diabetes, UK research suggests
Long-term exposure to air pollution and a lack of green space increases the risk of hospitalization for respiratory conditions
Better cardiovascular health in early pregnancy may offset high genetic risk
Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer
Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer
IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing
Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors
Just how dangerous is Great Salt Lake dust? New research looks for clues
Maroulas appointed Associate Vice Chancellor, Director of AI Tennessee
New chickadee research finds cognitive skills impact lifespan
Cognitive behavioral therapy enhances brain circuits to relieve depression
Terasaki Institute awarded $2.3 Million grant from NIH for organ transplantation research using organs-on-a-chip technology
Atoms on the edge
Postdoc takes multipronged approach to muon detection
Mathematical proof: Five satellites needed for precise navigation
Scalable, multi-functional device lays groundwork for advanced quantum applications
Falling for financial scams? It may signal early Alzheimer’s disease
Integrating MRI and OCT for new insights into brain microstructure
Designing a normative neuroimaging library to support diagnosis of traumatic brain injury
Department of Energy announces $68 million in funding for artificial intelligence for scientific research
DOE, ORNL announce opportunity to define future of high-performance computing
Molecular simulations, supercomputing lead to energy-saving biomaterials breakthrough
Low-impact yoga and exercise found to help older women manage urinary incontinence
Genetic studies reveal new insights into cognitive impairment in schizophrenia
Researcher develops technology to provide cleaner energy and cleaner water
Expect the unexpected: nanoscale silver unveils intrinsic self-healing abilities
nTIDE September 2024 Jobs Report: Gains in employment for people with disabilities appear to level off after reducing gaps with non-disabled workers
Wiley enhances NMR Spectral Library Collection with extensive new databases
[Press-News.org] Researchers take step toward development of universal COVID-19 antibodiesTexas Biomed and partners licensing new SARS-CoV-2 antibody targeting newest strains of COVID-19